Skip to main content
. Author manuscript; available in PMC: 2011 Aug 18.
Published in final edited form as: Bioconjug Chem. 2010 Aug 18;21(8):1565–1570. doi: 10.1021/bc1001467

Fig. 7.

Fig. 7

The percent injected dose (%ID) in the whole body, tumor and three normal organs at 2 and 6 h post administration of the 18F-MORF/Trastuzumab nanoparticle to a tumored mouse. Radioactivity quantitation was accomplished by using Syntegra version 2.0j program.